NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Merck & Co
»25/11/2009 [Company watch]
Merck Serono to Spend $225 Million on New Beijing R&D Center

Merck Serono, a division of Germany’s Merck KGaA (MRK), will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing center will be tasked with meeting unmet needs in China’s public health system. Merck Serono positioned the center as proof of the company’s commitment to the pharmaceutical market in China.

 

Merck Serono, a division of Germany’s Merck KGaA (MRK), will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing center will be tasked with meeting unmet needs in China’s public health system. Merck Serono positioned the center as proof of the company’s commitment to the pharmaceutical market in China.

The research activities in the Beijing center will focus on biomarker research including pharmacogenomics and bioanalytics activities. In addition, the center’s specific, and fairly diverse, goals are:

  • Develop drugs for China and other Asian countries;
  • Conduct local clinical trials and participate in global clinical trials;
  • Manage collaborations with research institutions in China; and
  • Seek new partnerships with local academic institutions and companies.

China is a country with talented scientists and high-quality research,” said Bernhard Kirschbaum, Executive Vice President, Research and Development for Merck Serono, in a statement. “We will recruit more R&D talent in China and build a world-class organization in China that will extend our global R&D expertise and capabilities.”

The China R&D organization will become one of the key R&D hubs for Merck Serono worldwide. Key hubs so far are Germany, Switzerland and the United States.

Merck Serono China, which has over 1,000 employees, offers drugs that treat a variety of diseases, including cancer (Erbitux®), multiple sclerosis (Rebif®), infertility (Gonal-f®), endocrine and metabolic disorders (Saizen®), as well as cardiometabolic diseases (Concor®, Euthyrox®).

Merck Serono was formed after the acquisition of the Swiss biopharma Serono by Merck in 2006. Soon after, Merck combined its ethical drug division into Serono’s operations, headquartered in Geneva. The American branch of Merck was split off from its German parent in 1917 and operates as a separate company. Merck kGaA had revenues of $11.4 billion in 2008.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.